AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Eli Lilly's Alzheimer's Drug Kisunla Gets Limited Approval in Europe
ByAinvest
Monday, Jul 28, 2025 2:32 am ET1min read
The European Medicines Agency (EMA) has granted limited approval to Eli Lilly's Alzheimer's drug Kisunla, reversing an earlier decision to reject the drug due to concerns over brain swelling and bleeding in patients. The treatment will be administered via a monthly infusion and is aimed at patients with early-onset Alzheimer's who do not have a copy of the ApoE4 gene. Eli Lilly's stock has a consensus Strong Buy rating among analysts, with an average price target of $1,006.80, implying 26.02% upside from current levels.
The European Medicines Agency (EMA) has granted limited approval to Eli Lilly's Alzheimer's drug Kisunla, reversing an earlier decision to reject the drug due to concerns over brain swelling and bleeding in patients. The treatment will be administered via a monthly infusion and is aimed at patients with early-onset Alzheimer's who do not have a copy of the ApoE4 gene.The EMA's Committee for Medicinal Products for Human Use (CHMP) initially recommended against the approval of Kisunla in March, citing the risk of potentially fatal events due to amyloid-related imaging abnormalities, involving swelling and potential bleeding in the brain. However, after Eli Lilly presented additional data, the CHMP has now backed the drug for use in certain patients with early symptomatic Alzheimer's disease in adults with confirmed amyloid pathology who are apolipoprotein E 4 heterozygotes or non-carriers.
The European Commission, which generally follows the CHMP's advice, will now review the recommendation, with a decision expected in the coming months. The U.S. Food and Drug Administration (FDA) had previously approved Kisunla, an antibody drug given as a monthly intravenous infusion that studies show has slowed the progression of Alzheimer's disease.
Eli Lilly's stock has a consensus Strong Buy rating among analysts, with an average price target of $1,006.80, implying 26.02% upside from current levels.
References:
[1] https://www.marketscreener.com/news/eli-lilly-wins-chmp-backing-of-kisunla-alzheimer-s-drug-ce7c5fdbd980f522
[2] https://investor.lilly.com/news-releases/news-release-details/donanemab-receives-positive-opinion-committee-medicinal-products
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet